European Multicentre Registry of Percutaneous Paravalvular Leak Closure — EuroPVL  

Quality of Life Clinical Trial

Official title: European Multicentre Registry of Percutaneous Paravalvular Leak Closure - EuroPVL Study

Status Recruiting

Clinical Trial Summary

Paraprosthetic cardiac valve leaks are a progressive complication after after surgical or percutaneous heart valve replacement. These leaks can lead to heart failure and/or life-threatening hemolysis.

Percutaneous closure of para-prosthetic leaks has been developed as an alternative to surgery in high-risk patients. These procedures remain technically challenging with a significant risk of failure and complications, but this risk is improved since the development of dedicated prostheses and the increased experience of the operators. The data in the literature concerning percutaneous leak closure remain limited and disparate and mostly retrospective.The impact of the procedures on the quality of life of patients is not known. Beyond the technical aspects and the follow-up of major cardiovascular events, investigators also wonder what is the impact of these procedures on the quality of life of patients. Investigators hypothesize that even a partial reduction in paraprosthetic leakage may be associated with an improvement in quality of life through reduction of transfusion needs and/or reduction of dyspnea. A prospective study is warranted to assess the technical and clinical and clinical results of these procedures, together with the evaluation of the the possible benefit on the quality of life of the patients.

Clinical Trial Description

OBJECTIVES OF THE STUDY MAIN OBJECTIVE To evaluate the clinical results of the transcatheter closure of para-prosthetic leaks.

SECONDARY OBJECTIVE Technical success of the procedure defined by successful placement of the prosthesis at the intended site with at least a 1 grade reduction in leakage and residual leakage grade 0-1 Change in quality of life after closure of para-prosthetic leakage at 3 months Evolution of clinical and biological markers of hemolysis and heart failure between at 3 months evolution of clinical markers of functional capacity 4. JUDGMENT CRITERIA 4.1 PRIMARY ENDPOINT

-Clinical success of the procedure:

Clinical success will be assessed on a composite endpoint at 2 years:

• vital status,

• hospitalization for heart failure,

• blood transfusion for hemolysis,

• surgical or percutaneous re-intervention on the treated valve. 4.2 SECONDARY ENDPOINTS The technical, echographic, biological and clinical data of the procedure and post procedure will be recorded as well as the complication rates. The EQ5D-5L quality of life score will be evaluated before the procedure, between 1 and 3 months, and post procedure.

STUDY POPULATION INCLUSION CRITERIA

To be included, each patient must meet all of the following conditions:

• Patients aged 16 years and older,

• Patients or the representative of the parental authority of the minor patient who does not object to participation in the observatory,

• Patients referred for a para-prosthetic leak closure procedure NON-INCLUSION CRITERIA Patients presenting at least one of the following criteria cannot be included

• Patients under 16 years of age,

• Refusal of the patient or the representative of the parental authority of the minor patient to participate in the observatory. ;

Related Conditions & MeSH terms

• Aortic Valve Insufficiency
• Cardiac Valve Disease
• Heart Valve Diseases
• Mitral Valve Insufficiency
• Outcomes
• Paravalvular Aortic Regurgitation
• Paravalvular Leak
• Quality of Life

• NCT number: NCT05506293
• Study type: Observational [Patient Registry]
• Source: Centre Chirurgical Marie Lannelongue
• Contact: Sebastien Hascoet, MD, PhD
• Phone: 0033140942429
• Email: s.hascoet@ghpsj.fr
• Status: Recruiting
• Start date: January 1, 2020
• Completion date: July 1, 2026